133 related articles for article (PubMed ID: 17196514)
21. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
[TBL] [Abstract][Full Text] [Related]
22. [Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice].
Campone M; Fumoleau P
Bull Cancer; 2002 Mar; 89(3):275-82. PubMed ID: 11940467
[TBL] [Abstract][Full Text] [Related]
23. [Case Report on Treatment of Metastatic Breast Cancer with Trastuzumab during Pregnancy].
Rasenack R; Gaupp N; Rautenberg B; Stickeler E; Prömpeler H
Z Geburtshilfe Neonatol; 2016 Apr; 220(2):81-3. PubMed ID: 27111595
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab treatment for breast cancer during pregnancy.
Shrim A; Garcia-Bournissen F; Maxwell C; Farine D; Koren G
Can Fam Physician; 2008 Jan; 54(1):31-2. PubMed ID: 18208949
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
[TBL] [Abstract][Full Text] [Related]
26. [Examination of therapy using trastuzumab in patients with metastatic breast carcinoma].
Nohara T; Iwamoto M; Kobayashi T; Lee SW; Sumiyoshi K; Tanigawa N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1651-4. PubMed ID: 14619486
[TBL] [Abstract][Full Text] [Related]
27. Effect of adjuvant trastuzumab on pregnancy.
Waterston AM; Graham J
J Clin Oncol; 2006 Jan; 24(2):321-2. PubMed ID: 16401684
[No Abstract] [Full Text] [Related]
28. Cardiac dysfunction in clinical trials of trastuzumab.
Page E; Assouline D; Brun O; Coeffic D; Fric D; Winckel P
J Clin Oncol; 2002 Oct; 20(19):4119; author reply 4120. PubMed ID: 12351610
[No Abstract] [Full Text] [Related]
29. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
30. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
31. HER2 and response to paclitaxel in node-positive breast cancer.
Roukos DH
N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18193530
[No Abstract] [Full Text] [Related]
32. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
Ahluwalia MS; Daw HA
J Clin Oncol; 2005 Oct; 23(30):7759-60; author reply 7760-1. PubMed ID: 16234551
[No Abstract] [Full Text] [Related]
33. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins.
Cohen AD; Mermershtain W; Geffen DB; Schoenfeld N; Mamet R; Cagnano E; Cohen Y; Halevy S
J Dermatolog Treat; 2005 Feb; 16(1):19-21. PubMed ID: 15897162
[TBL] [Abstract][Full Text] [Related]
35. HER2 and response to paclitaxel in node-positive breast cancer.
Ferretti G; Felici A; Cognetti F
N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18184969
[No Abstract] [Full Text] [Related]
36. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
Andre F; Campone M; O'Regan R; Manlius C; Massacesi C; Sahmoud T; Mukhopadhyay P; Soria JC; Naughton M; Hurvitz SA
J Clin Oncol; 2010 Dec; 28(34):5110-5. PubMed ID: 20975068
[TBL] [Abstract][Full Text] [Related]
38. HER2 and response to paclitaxel in node-positive breast cancer.
Nash I
N Engl J Med; 2008 Jan; 358(2):198; author reply 198-9. PubMed ID: 18193532
[No Abstract] [Full Text] [Related]
39. Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy--Case report and updated literature review.
Shrim A; Garcia-Bournissen F; Maxwell C; Farine D; Koren G
Reprod Toxicol; 2007 Jun; 23(4):611-3. PubMed ID: 17399946
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Dawood S; Gonzalez-Angulo AM; Peintinger F; Broglio K; Symmans WF; Kau SW; Islam R; Hortobagyi GN; Buzdar AU
Cancer; 2007 Sep; 110(6):1195-200. PubMed ID: 17647266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
